Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1807503-92-9

Post Buying Request

1807503-92-9 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1807503-92-9 Usage

Description

Bromo-PEG2-acid is a PEG linker containing a bromide group and a terminal carboxylic acid. The hydrophilic PEG spacer increases solubility in aqueous media. The bromide (Br) is a very good leaving group for nucleophilic substitution reactions. The terminal carboxylic acid can react with primary amine groups in the presence of activators (e.g. EDC, or HATU) to form a stable amide bond.

Uses

Bromo-PEG2-acid is a heterobifunctional, PEGylated crosslinker featuring a bromo group at one end and a carboxyl group at the other. The hydrophillic PEG linker facilitates solubility in biological applications. Bromo-PEG2-acid can be used for bioconjugation or as a building block for synthesis of small molecules, conjugates of small molecules and/or biomolecules, or other tool compounds for chemical biology and medicinal chemistry that require ligation. Examples of applications include its synthetic incorporation into antibody-drug conjugates or proteolysis-targeting chimeras (PROTAC? molecules) for targeted protein degradation.

Check Digit Verification of cas no

The CAS Registry Mumber 1807503-92-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,0,7,5,0 and 3 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1807503-92:
(9*1)+(8*8)+(7*0)+(6*7)+(5*5)+(4*0)+(3*3)+(2*9)+(1*2)=169
169 % 10 = 9
So 1807503-92-9 is a valid CAS Registry Number.

1807503-92-9Downstream Products

1807503-92-9Relevant articles and documents

PCSK9 ANTAGONIST COMPOUNDS

-

Page/Page column 65; 66, (2021/03/05)

Disclosed are compounds of Formula (A), or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula (I) or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1807503-92-9